Catbird
Senior Moderator
NEWS RELEASE
ALABAMA DEPARTMENT OF PUBLIC HEALTH
RSA Tower 201 Monroe Street, Suite 914 Montgomery, AL 36104
Phone 334-206-5300 Fax 334-206-5534
www.adph.org
Alabama health officials begin investigation of product from compounding pharmacy
FOR IMMEDIATE RELEASE
CONTACT:
Mary McIntyre, M.D., M.P.H.
(334) 206-5971
The Alabama Department of Public Health is participating with other local, state and federal health agencies in an investigation of products prepared by a compounding manufacturer, Main Street Family Pharmacy of Newbern, Tenn., that were shipped to clinics in 13 states, including one clinic in Alabama.
The Alabama investigation began after the U.S. Food and Drug Administration was notified of individuals who developed complications after administration of an injectable steroid product. Main Street Family Pharmacy has issued a voluntary recall of all sterile products that it has produced.
State and local public health officials are working with the Alabama clinic that received the formulation of methylprednisolone acetate (MPA), a
steroid product, associated with the investigation. MPA is typically used for reducing inflammation.
At this time, the clinic will begin notifying patients who may have been exposed to the product to alert them to report any signs and symptoms of complications. The Alabama Board of Pharmacy has also been contacted.
This investigation is still very early and rapidly evolving. Information is subject to change.
5/24/13
xhttp://www.adph.org/news/assets/130524.pdf
ALABAMA DEPARTMENT OF PUBLIC HEALTH
RSA Tower 201 Monroe Street, Suite 914 Montgomery, AL 36104
Phone 334-206-5300 Fax 334-206-5534
www.adph.org
Alabama health officials begin investigation of product from compounding pharmacy
FOR IMMEDIATE RELEASE
CONTACT:
Mary McIntyre, M.D., M.P.H.
(334) 206-5971
The Alabama Department of Public Health is participating with other local, state and federal health agencies in an investigation of products prepared by a compounding manufacturer, Main Street Family Pharmacy of Newbern, Tenn., that were shipped to clinics in 13 states, including one clinic in Alabama.
The Alabama investigation began after the U.S. Food and Drug Administration was notified of individuals who developed complications after administration of an injectable steroid product. Main Street Family Pharmacy has issued a voluntary recall of all sterile products that it has produced.
State and local public health officials are working with the Alabama clinic that received the formulation of methylprednisolone acetate (MPA), a
steroid product, associated with the investigation. MPA is typically used for reducing inflammation.
At this time, the clinic will begin notifying patients who may have been exposed to the product to alert them to report any signs and symptoms of complications. The Alabama Board of Pharmacy has also been contacted.
This investigation is still very early and rapidly evolving. Information is subject to change.
5/24/13
xhttp://www.adph.org/news/assets/130524.pdf